OBJECTIVE: @entity4153 of the cervix (SCNECC) is a rare @entity5 and has a high mortality despite of aggressive surgical treatment. The aims of this study were to determine the prognostic factors associated with the survival of surgically treated @entity1 with early-stage SCNECC and to see whether @entity3003 plus @entity1311 (TC) therapy after surgery can improve their survival. METHODS: Thirty-eight @entity1 with FIGO stages @entity9217 (n = 1), @entity3846 (n = 31), @entity3847 (n = 3), and IIA1 (n = 3) were treated with radical hysterectomy, followed by adjuvant TC or non-TC, with or without radiotherapy, in our hospital between 2004 and 2013. Medical charts and clinical data were retrieved and retrospectively reviewed. The Kaplan-Meier method and Cox regression model were used for survival analysis. RESULTS: The mean age of @entity1 were 40.4    7.0 years. The preoperative detection rate of SCNECC was only 34.2%. The overall 1-, 2-, and 5-year survival rate was 81.6%, 54.7%, and 43%, respectively, whereas the 1-, 2-, and 5-year cumulative recurrence rate was 37.8%, 44.2%, and 49.3%, respectively. For @entity1349 ( @entity1349 ), the univariate survival analysis indicated that @entity5 homology, parametrial invasion, chemotherapy regimens, and chemotherapy courses were risk factors. For disease-free survival, the univariate survival analysis identified lymph node involvement, @entity5 homology, parametrial invasion, chemotherapy regimens, and chemotherapy courses as risk factors. However, when multivariable Cox regression model was used, only parametrial invasion and postoperative chemotherapy regimen were identified as risk factors for both @entity1349 (P = 0.037 and P = 0.016) and disease-free survival (P = 0.044 and P = 0.018). CONCLUSIONS: @entity4153 of the cervix is a @entity5 . Postoperative TC chemotherapy may improve the @entity1349 and disease-free survival in @entity1 with early-stage SCNECC.

Prognostic Factors of Surgically Treated Early-Stage XXXX of the Cervix.

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity4153 :: ('MESH:D018288', 'Disease') :: ['Small cell neuroendocrine carcinoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['deadly variant of cervical cancer', 'tumor', 'malignancy'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity3846 :: ('9479', 'Gene') :: ['IB1'] @entity9217 :: ('5798', 'Gene') :: ['IA2'] @entity3847 :: ('23542', 'Gene') :: ['IB2'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity4153 :: (MESH:D018288,Disease) :: ['Small Cell Neuroendocrine Carcinoma']
